L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma

Journal of Surgical Oncology

Volumn 103, Issue 7, 2011, Pages 669-673

  Tsutsumi, Shinji ^a   Morohashi, Satoko ^a   Kudo, Yasuyuki ^a   Akasaka, Harue ^a   Ogasawara, Hiroshi ^a   Ono, Masashi ^a   Takasugi, Kaori ^a   Ishido, Keinosuke ^a   Hakamada, Kenichi ^a   Kijima, Hiroshi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

cancer invasion; immunohistochemistry; L1CAM (L1 cell adhesion molecule); pancreatic ductal adenocarcinoma; prognosis

Indexed keywords

MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE L1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEURAL CELL ADHESION MOLECULE L1; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955479794     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21880     Document Type: Article

References (33)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan. Vital Statistics of Japan (Ministry of Health, Labour and Welfare). [Accessed March 1, 2010].
2. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. (Pubitemid 46148091)
3. Moos M, Tacke R, Scherer H, et al.: Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 1998; 334: 701-703.
4. Schachner M,: Neural recognition molecules and synaptic plasticity. Curr Opin Cell Biol 1997; 9: 627-634. (Pubitemid 27424918)
5. Tsuzuki T, Izumoto S, Ohnishi T, et al.: Neural cell adhesion molecule L1 in gliomas: Correlation with TGFbeta and p53. J Clin Pathol 1998; 51: 13-17. (Pubitemid 28122578)
6. Thies A, Schachner M, Moll I, et al.: Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer 2002; 38: 1708-1716.
7. Zecchini S, Bianchi M, Colombo N, et al.: The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008; 68: 1110-1118. (Pubitemid 351272229)
8. Fogel M, Gutwein P, Mechtersheimer S, et al.: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003; 362: 869-875. (Pubitemid 37130096)
9. Kaifi JT, Reichelt U, Quaas A, et al.: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007; 20: 1183-1190. (Pubitemid 47609067)
10. Boo YJ, Park JM, Kim J, et al.: L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 2007; 14: 1703-1711. (Pubitemid 46790990)
11. Gavert N, Conacci-Sorrell M, Gast D, et al.: L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168: 633-642. (Pubitemid 40271028)
12. Kodera Y, Nakanishi H, Ito S, et al.: Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer. Anticancer Res 2009; 29: 4033-4040.
13. Schroder C, Schumacher U, Fogel M, et al.: Expression and prognostic value of L1-CAM in breast cancer. Onco Rep 2009; 22: 1109-1117.
14. Ben QW, Wang JC, Liu J, et al.: Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010; 17: 2213-2221.
15. Kaifi JT, Zinnkann U, Yekebas EF, et al.: L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J Gastroenterol 2006; 12: 94-98. (Pubitemid 43126090)
16. Gast D, Riedle S, Issa Y, et al.: The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008; 27: 1281-1289. (Pubitemid 351294696)
17. Arlt MJ, Novak-Hofer I, Gast D, et al.: Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006; 66: 936-943. (Pubitemid 43165961)
18. Knogler K, Grunberg J, Zimmermann K, et al.: Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res 2007; 13: 603-611. (Pubitemid 46225367)
19. Bao S, Wu Q, Li Z, et al.: Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008; 68: 6043-6048.
20. Japan Pancreas Society, editors: General rules for the study of pancreatic cancer. 6th edition. Tokyo: Kanehara; 2009 [in Japanese].
21. Sobin LH, Gospodarowicz MK, Wittekind CH, editors: TNM classification of malignant tumours. 7th edition. New York: Wiley-Blackwell; 2009.
22. Kloppel G, Hruban RH, Longnecker DS, et al.: Ductal adenocarcinoma of the pancreas. In:, Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. pp. 221-230.
23. Huszar M, Moldenhauer G, Gschwend V, et al.: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 2006; 37: 1000-1008. (Pubitemid 44097029)
24. Takahashi T, Ishikura H, Motohara T, et al.: Perineural invasion by ductal adenocarcinoma of the pancreas. J Surg Oncol 1997; 65: 164-170. (Pubitemid 27351703)
25. Ozaki H, Hiraoka T, Mizumoto R, et al.: The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999; 29: 16-22. (Pubitemid 29058554)
26. Mechtersheimer S, Gutwein P, Agmon LN, et al.: Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001; 155: 661-674.
27. Thelen K, Kedar V, Panicker AK, et al.: The neural cell adhesion molecule L1 potentiates integrin-dependent cell migration to extracellular matrix proteins. J Neurosci 2002; 22: 4918-4931. (Pubitemid 37465607)
28. Silletti S, Yebra M, Perez B, et al.: Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem 2004; 279: 28880-28888. (Pubitemid 38915755)
29. Meier F, Busch S, Gast D, et al.: The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 2006; 119: 549-555. (Pubitemid 43955707)
30. Gast D, Riedle S, Schabath H, et al.: L1 auguments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int J Cancer 2005; 115: 658-665. (Pubitemid 40656727)
31. Gavert N, Sheffer M, Raveh S, et al.: Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 2007; 67: 7703-7712. (Pubitemid 47281363)
32. Stoeck A, Gast D, Sanderson MP, et al.: L1-CAM in a membrane-bound or soluble form auguments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol 2007; 104: 461-469. (Pubitemid 46156956)
33. Sebens Muerkoster S, Werbing V, Sipos B, et al.: Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007; 26: 2759-2768. (Pubitemid 46663831)